Direct Answer
European pharmaceutical companies are drugmakers based in the United Kingdom, Switzerland, Germany, France, Denmark and neighboring countries that sell globally. Their results mix US pricing, European health system pricing and currency translation.
Industry Overview
European Pharmaceuticals sits within the health care sector. The first numbers to compare across companies here are sales growth at constant currency, share of US revenue and pipeline and late-stage readouts. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Sales growth at constant currency: Sales change with exchange rate effects removed. These firms report in euros, francs or pounds but sell widely in dollars, so it shows underlying demand rather than currency translation.
- Share of US revenue: Portion of sales generated in the United States, the highest-priced large market. A higher share raises exposure to US pricing policy and rebates, while a lower share leans on European reimbursement.
- Pipeline and late-stage readouts: Drug candidates in phase 3 and results from those trials. Late-stage results often decide whether future launches offset patent losses, so check stage mix as well as count.
- Core operating margin: Operating profit after stripping out items such as amortization and one-off charges, as each company defines it. Compare definitions across firms, since the adjustments differ.
- Patent expiry exposure: Share of sales from drugs losing exclusivity in coming years. High exposure means revenue must be replaced by launches or acquisitions to keep growing.
Primary Macro Drivers
- US drug pricing and rebates: A large share of profit comes from the United States, so changes in pricing, rebates or coverage there move sales growth and core operating margin.
- European reimbursement and health technology assessments: European governments set prices and decide coverage through assessment bodies, which limits price and slows or restricts uptake of new products.
- Currency moves against the dollar and euro: Reported results are translated from several currencies, so a stronger or weaker dollar changes reported sales and profit even when volumes are unchanged.
- New product launches: New products with strong uptake offset older ones losing exclusivity, so launches determine sales growth at constant currency.
Major Risks
- Patent cliffs: When key drugs lose exclusivity, cheaper copies take volume and sales fall sharply; watch patent expiry exposure against late-stage pipeline.
- US pricing reform: Changes to US rebates, negotiation or coverage would cut net prices on a big share of sales; watch the share of US revenue and net price trends.
- Currency swings: Translation and transaction effects move reported sales and profit; analysts watch results at constant currency versus reported figures.
- Late-stage trial failures: A failed late-stage study removes expected future revenue and can lead to write-downs; watch pipeline readout dates and impairments.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Mature |
| Geographic Importance | Global |
Finding Companies in European Pharmaceuticals
The SEC's Standard Industrial Classification has no code that describes european pharmaceuticals as a group, so this profile does not list companies for it. Filers are classified by their main business, and a company in this industry may sit under a broader code.
To find individual companies, use the company directory and the health care hub. Nothing here is a list of recommendations.
Where to Go Next
The European Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Fertility Services
- Electronic Health Records
- Gene Editing
- Drug Discovery Platforms
- Gene Therapy
- Digital Therapeutics
- Generic Pharmaceuticals
- Dialysis Centers
Put it to work
Frequently Asked Questions
What are the main KPIs for the European Pharmaceuticals industry?
Key performance indicators for the European Pharmaceuticals industry include: Sales growth at constant currency, Share of US revenue, Pipeline and late-stage readouts, Core operating margin, Patent expiry exposure. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the European Pharmaceuticals industry?
The European Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the European Pharmaceuticals industry?
The primary risks for European Pharmaceuticals companies include: Patent cliffs, US pricing reform, Currency swings, Late-stage trial failures. Investors should assess each company's exposure to these factors and its track record of navigating them.